Opportunistic Infection Updates, Richard A. Murphy, MD, MPH Harbor-UCLA Medical Center Geffen School of Medicine at UCLA
|
|
- Robert Rice
- 5 years ago
- Views:
Transcription
1 Opportunistic Infection Updates, 2018 Richard A. Murphy, MD, MPH Harbor-UCLA Medical Center Geffen School of Medicine at UCLA
2 Objectives 1. Describe context for persistence of OIs globally 2. Provide updates on the diagnosis & treatment of OIs
3 Deaths in HIV-infected persons with advanced HIV disease Number of deaths, millions Despite the number receiving ART >20 million globally, total deaths in those with advanced HIV have declined slowly Total number on ART Number of deaths in advanced HIV Year Calmy et al CID 2018:66 (Suppl 2)
4 What proportion of patients begin ART with very advanced disease with CD4 cell count <100 in South Africa today? 1. 1 in 10 patients 2. 1 in 5 patients 3. 1 in 2 patients 4. None of the above
5 Patients are presenting to care with advanced HIV in South Africa Nationwide lab data from South Africa (NHLS) % entering care with CD4 <100 estimated (red) From , % entering care w/ CD4<100 declined From 2011 on, % starting ART w/ CD4<100 not 2016: 17% CD4<100 Men 2x as likely as women Clin Infect Dis Apr 1; 66(Suppl 2)
6 RFs for late presentation with advanced HIV in SA In 35 PHCs from 3 high burden districts in SA, >12,000 newly diagnosed patients during % had CD4 < 200 at 1 st visit Risk factors for presentation with CD4<200: >50 years old, OR 3.4 (95% CI: ) Male, OR 2.7 (95% CI: ) Accessing care in urban inner city or urban township ~ OR 1.5 Very late presentation in SA overly represented by older males, accessing care in urban inner cities and townships Fomundam HN, et al. SAMJ 2018
7 Other reasons we still see patients with advanced HIV & OIs - Not all with HIV receive continuous care - Reasons include migration, incarceration, mental illness - Not all on ART achieve durable virologic suppression - Inadequate adherence in certain patient subgroups - Failure from drug resistance with NNRTI-based regimens
8 Advanced HIV disease in African hospitals: Most patients are ART-experienced Homa Bay, Kenya (N=338) prospective study of HIV-infected admitted: 85% aware of HIV status at admission 65% ART-experienced 2/3 receiving ART failing with VL>1000 Recent Edendale, SA prospective study of HIV-infected admitted: 84% aware of status 79% were currently taking ART Homa Bay City, Kenya Ousely et al CID 2018:66 (Suppl 2) Gupta-Wright et al Lancet 2018; 392:
9 ART-experienced patients with OIs in Africa One contributor? Late recognition of ART treatment failure One contributors may be under-recognition in clinics of 1 st line ART failure (VL > 1000) Multiple studies: Patients with 1 st line failure not identified & switched promptly with switch delays of 4-6 months common Why? Reporting delays, clinician switch reluctance, poor patient follow-up Delayed 2 nd line ART switch linked in 3 African countries with incr. risk of OI/ death Cost for 2nd line regimens <$250/year AIDS Res Hum Retroviruses Dec;33(12):
10 Fewer deaths if 2 nd line switch occurred after 1 VL >1000 With individual-based model of HIV progression, effect of 2 policies compared: (1) Switch after 1 VL > 1000 for those failing EFV-based ART (2) Switch after 2 VL values > 1000 Shroufi et al 22 nd IAC, nd IAC, Amsterdam
11 Case 1 26 yo HIV+ male with unknown CD4 count presents with 2 months of cough, fever and wt loss Previously on EFV-based first-line ART but no ART x 12 months and not taking cotrimoxazole. Over 24 hrs, acute on chronic shortness of breath ID Images, 2006 Peter Lokken and Richard Murphy
12 Case 1 Exam HR 126, RR 26, Temp 37.5, BP 95/53, O2 96% RA + oral thrush, no rash, absent BS on L Data WBC 14.5, Hb 11.6, PLT 298 and bicarb 14 meq/l ABG: 7.47 / pco2 26 mm Hg / po2 161 mm Hg supplemental O 2. EKG: Sinus tachycardia
13 Seriously ill HIV infected patients admitted in Cape Town with cough HIV-infected + cough any length hospitalized with >1 WHO danger sign N=484 (median CD4 89), 35% on ART at admission 12% died Linked with mortality: on ART at admission, unable to walk, low CD4 Among those on ART, 1/2 initiated within 6 months and 1/3 virologically failing Other WHO danger signs not linked w/mortality WHO Danger Signs: Cannot stand Temp >39C (102) RR > 30 HR > 120 Medical officer discharge diagnosis: - TB (62%) - Pneumonia (52%) - PCP (10%) - Other (3%) Griesel et al. AIDS Res Ther (2018) 15:5
14 Making the diagnosis of PCP with few tools What available tests suggest PCP in adv. HIV admitted to hosp. (in absence of histological diagnosis or CT)? PCP dx ed by> 1000 copies/ml of DNA by PCR Probability of PCP: 4 pts (25%), 5 pts (42%), 6 pts (61%) Model Assuming Access to Pulse Oximetry: SAJHIVM. 2018;19(1), a851. *Refer PCP to ICU? Cape Town: Mort. in PCP with resp. failure in ICU 60% with 98% intubated 25% with TB coinfection. PCP mortality in ICU in SA similar to hi income (Chiliza N PLOS One, 2018)
15 Chest x-ray What is the most likely diagnosis? A. Pneumocystis pneumonia B. Pulmonary tuberculosis C. Pulmonary cryptococcosis D. Pulmonary Kaposi s sarcoma
16 Case 1 Sputum samples revealed acid-fast bacilli What if the patient was not able to produce sputum? Any tests that could improve diagnostic yield if tuberculosis suspected in patient with CD4 < 100?
17 Added yield of urine LAM in HIV-infected inpatients RCT in S Africa + Malawi of consecutive inpatients with HIV N= 2600, 1/3 had CD4<100 - Any CD4 cell count, no current TB Rx - Standard arm: Sputum Xpert MTB/RIF - Intervention: Sputum Xpert + urine LAM + urine Xpert - 56-day mortality: No difference overall - 40% confirmed TB, only LAM positive - Among CD4<100 and in severe anemia, mortality was reduced 7%, with difference appearing after d/c Ankur Gupta-Wright CROI 2018 Poster 1117 Low added yield of urine Xpert
18 Urine LAM Activism at IAC Amsterdam, 2018
19 Case 1 A chest tube was placed. CD4 results: 78 cells/mm 3
20 Case 1 Four drug standard TB therapy was initiated with plan for initiation of ART within 2 weeks. What is the risk for immune reconstitution inflammatory syndrome (IRIS) in this patient and what can be done?
21 Paradoxical TB- IRIS Paradoxical TB-IRIS is a common complication when TB patients and low CD4 start on ART Meta-analysis: Incidence ~18% Hospitalization in 25% TB IRIS-related mortality 2% Major RFs Low CD4 cell count at ART start ART started rapidly after TB diagnosis, now standard of care with advanced HIV infection Presents with new / recurrent inflammatory features typically in first 4 wks of ART Slide courtesy of Graeme Mentjes
22 Impact of corticosteroids in preventing IRIS in HIV-associated TB RCT in Cape Town of prednisone vs. placebo in TB among HIV-infected at high risk for IRIS - N= CD<100 + ART naïve on TB therapy - Prednisone 40 mg/day for 2 wk; then 20 mg/day for 2 wk vs. placebo at start of ART - Risk of TB IRIS lower in prednisone group: 33% vs 47%, RR No diff. in mortality, infections, cancer. - Fewer hospitalizations in prednisone arm Slide courtesy of Raj Gandhi, MD
23 Case 1 With lung re-expansion, a parenchymal cavity was evident The patient was referred for outpatient ART ART was initiated 2 wks after initiation of TB therapy (without cortiosteroids)
24 Case 2 43 yo man comes to clinic with 2 weeks of HA, dizziness, and according to family rapid development of confusion 9 kg weight loss over 3 months No known PMH Rapid HIV test positive
25 Case 2 Exam: 37.2 HR 93 BP 118/70 RR 14 97% RA Tired but arousable and oriented No nuchal rigidity, non-focal neurological exam Data: LP: 4 WBCs, 55 RBC. Glucose very depressed. Protein mildly elev. India ink stain positive Opening pressure 52 cm of H2O
26 Elevated intracranial pressure linked with poor outcomes in CCM but manometers not routinely available
27 Using CSF flow rate during LP to measure ICP In Cape Town, 32 patients with CCM underwent 89 LPs with 22-G spinal needle. ICP was first measured with a manometer and then CSF flow rate in drops/min counted. Using 40 drops/minute cut-off, sensitivity was 91% for detecting raised ICP > 25 cm of H2O Only 5% of LPs misclassified with drop rate as normal when ICP actually elevated. When manometers not available, ICP can be accurately estimated with CSF drops/min with possible threshold of >40 drops/min. J Acquir Immune Defic Syndr 2017;74:e64 e66
28 Case 2 This patient (USA) received liposomal amphotericin B + 5-FC as initial induction therapy He received saline hydration (1 L NS) and K before IV dosing He developed acute renal failure by day 7 with GFR of 53 ml/min (reduced from 105 ml/min)
29 How common is acute kidney injury (GFR to <60 ml/min) in patients with CCM who receive amphotericin B deoxycholate and is there impact on subsequent mortality? 1. 20% develop AKI with no impact on mortality as AKI is reversible 2. 20% develop AKI with increased mortality 3. 40% develop AKI with no impact on mortality as AKI is reversible 4. 40% develop AKI with increased mortality
30 AKI common in CCM managed with AmB and mortality Substudy of large clinical trial of AmB + fluconazole in Uganda and SA. * AKI defined as CrCl of <60 ml/min AKI developed in ~40%; mean time to onset ~ 1 wk with RFs: Development of urine protein early on treatment Hi CD4 Med. CD4: AKI (CD4 49) vs. No AKI (CD4 14) AKI was associated with mortality: AKI: 10 wk mort: 51% No AKI: 10 wk mort: 29% (P=0.01) All patients with severe AKI (GFR <30 ml/min) died In all those surviving, AKI fully resolved Future role for 5-FC? **SA recs: W/ onset of AKI (Cr 2x) - hold AmB + incr. saline hydration + monitor If no improvement, cont. with (renal adjusted) fluconazole monotherapy Schutz C et al; OFID Govender et al SAJHIV Cryptococcal meningitis guidelines
31 Induction treatment recommendations S Africa 2 wks of AmB (1 mg/kg/day) plus fluconazole 800 mg/day Based in part on Viet. study in which this regimen had mortality similar to 4 wks of AmB monotherapy but had higher rates of CSF culture clearance The study also influenced WHO recs that recommended 2 wks of AmB + fluconazole WHO now recommends 1 wk of AmB +5-FC for induction phase of treatment. Why? Day et al NEJM 368;14 April 4, 2013
32 ACTA CCM trial ACTA trial, N=721 with CCM randomized (median CD4 25) in Malawi, Zambia, Cameroon, Tanzania Daily therapeutic LPs performed when OP elevated Patients randomized to AmB received 1 L NS daily, K and Mg suppl. Pts randomized to oral regimen, 1 wk of AmB or 2 wks of AmB. Next, AmB recipients randomized to flucon. or 5-FC. - 1 Oral arm: - Fluconazole [1200 mg/day] + Flucytosine (5FC) [100 mg /kg/day] for 2 wks - 4 IV arms : - 1 wk of amphotericin B (1 mg/kg/day) + oral drug - 2 wks of amphotericin B (1 mg/kg/day) + oral drug Malloy SF et al NEJM 2018
33 Antifungal combinations Mortality by study arm: Results : - At 10 weeks, lowest mortality was in the AmB + 5-FC group 1 week group - As partner drug, 5-FC superior to fluconazole = 40% reduction in death - Fully oral regimen met non inferiority outcomes for mortality - Option if IV/monitoring not feasible? - AmB regimens of more than 1 week linked with high rates of anemia The best arm was amphotericin B + 5-FC given 7 days The worst arm was amphotericin B + fluconazole 7 days Oral regimen 1 wk amphotericin 2 wk amphotericin
34 Flucytosine (5-FC) access where are we? 5-FC developed in 1957 Intracellular modification to 5-FU, joins fungal RNA, inhibits prot. synth. In lab, made during synthesis of FTC - off patent for decades! US cost $$$ = price manipulation by generic co s - Valeant 5-FC access virtually non-existent in LMICs but may be changing France: 5-FC sold by Meda Pharma $120 /14 days. Acquired by Mylan 2018: Mylan filed to register it with the WHO Prequalification Team (quality auditing for LMICs) opening door to broader access Mylan must register it in countries for 5-FC to become available Next step is pushing for wider access to liposomal amphotericin B...
35 Case 2 The patient has persistently elevated ICP of >30 cm of H2O After 2 weeks of induction therapy a VP shunt was placed The patient was demonstrated to be culture negative and was switched to fluconazole 400 mg/day as consolidation therapy. The plan was to initiate ART after 5-6 weeks
36 Question: After 2 wks of induction therapy with AmB and fluconazole, what proportion of patients still have positive CSF fungal culture with viable cryptococci? A. 5% B. 20% C % D. None of the above
37 Fluconazole consolidation for CCM 400 mg/day sufficient? After 2 wks of AmB-based induction, up to 50% have viable C. neoformans in CSF CSF culture (+) after induction linked mort. As consolidation, fluc. 400 mg/day common but efficacy demonstrated after AmB + 5FC Sterile CSF Non-sterile CSF Impact of high-dose fluconazole consolidation tested in 2015 substudy After induction, patients received fluconazole 800 mg/day until CSF sterile, median 40 days With this strategy, relationship the mortality impact of (+) CSF culture at end of induction no longer observed and dosing was well tolerated Mortality week 2-6, post induction CSF culture (+) 35% vs post induction CSF culture (-) 27% Open Forum Infect Dis Dec 28;2(4)
38 A different consolidation paradigm until 5-FC is accessible? In the COAT study residually CSF (+) patients required a median of 40 days of high dose fluconazole 800 mg/day Overall mortality through 48 weeks AIDS Research and Hum Retro. Vol 34, No. 5, 2018
39 CrAg titer predicts CSF cryptococcal disease Ethiopian study, all serum CrAg positive patients were offered LP, not just symptomatic CrAg <1:80 0% CSF CrAg positive CrAg 1:160 to 1:640 65% CSF CrAg positive CrAg >1: % CSF CrAg positive Significance of CNS symptoms in CrAg (+) patients? 1/3 of CrAg (+) patients with CNS cryptococcal disease had no symptoms; all had plasma CrAg >1:160 CID 2018; 66 (S2) S152-9 Policy implications? May be worthwhile to calculate titers for plasma CrAg (+) and be more assertive with CSF eval. particularly for those with plasma CrAg of >1:160
40 Case 3 25 yo female HCW with a history of cough and fever initiated standard TB therapy based on CXR w/ LUL infiltrate + hilar LAN 4 wks into treatment, the patient had a seizure and was admitted. At admission the HIV status was not known. CT head was normal CSF: 4 PMLs/uL and 2 lymphs/ul, elevated protein, mildly depressed glucose, CrAg negative, no opening pressure TB meningitis was suspected
41 Absence of CSF pleocytosis in HIV-associated TB-M Background: Absence of pleocytosis common in CCM but can this be the case in TB meningitis? Cohort study, Uganda In 85 microbiologically-confirmed, HIV-associated TBM cases, 28 (33%) had <5 cells CSF and in this group mortality was 39% Combining cohorts in Uganda, Zimbabwe, Brazil and Vietnam absence of CSF pleocytosis in 12% of HIV-associated TB-M and was associated with poor prognosis International Journal of Infectious Diseases 68 (2018) 77 78
42 Case 3 The patient was found to be HIV-infected with a CD4 cell count of 42 cells/ul How can the diagnosis of TB-M be confirmed?
43 TB meningitis and Xpert MTB/RIF Ultra Prospective study of Xpert MTB/RIF Ultra, a re-engineered PCR-based assay N=129 HIV infected adults with suspected meningitis 22 of 129 diagnosed with TB-M by composite standard of any (+) micro test 21/22 cases captured by Xpert Ultra consistent with a 95% sensitivity. Time to + result was 1 d vs med. 7 d for MGIT. Negative predictive value of Xpert Ultra was 99% (106 of 107 negative cases) If the Xpert Ultra was negative, TB-M virtually never present Lancet Infect Dis 2018; 18: patients with TB-M diagnosed by at least 1 diagnostic test
44 Case 3 The diagnosis of TB-M was suspected clinically. The patient initiated empirically on 4 drug antituberculosis therapy + corticosteroids.
45 Other updates
46 Ready-to-use supplementary food in advanced HIV with TB Subjects: CD4<100 and underweight with TB coinfection Peanut-based RUSF 1000 kcal/day for 12 weeks vs. none. N=1805, median CD4 34 and with BMI <18.5 in 40% Despite greater weight gain, no effect on mortality at 24 or 48 wks No benefit in those with lower BMI It was not designed to look at impact on retention and such an effect may exist Overall mortality through 48 weeks Mallewa J, et al The Lancet HIV, Volume 5, 2018
47 Growth of AMR as a threat to patients with HIV-infection Lab-based study of blood cultures without patient-level information from 2 Ugandan hospitals; 2011 CLSI Standards followed 462 (14%) isolates grown from ~3,000 blood cultures Gram-positive isolates most commonly S. aureus 1/3 of S. aureus were MRSA, only 4% sensitive to TMP/SMX Gram-negatives Most common: E coli, 33% sensitive to ceftriaxone, 40% sensitive to cipro Klebsiella, 15% sensitive to ceftriaxone, 23% sensitive to cipro Salmonella isolates, 50% MDR with resistance to 3 drug classes Kajumbula et al EID 2018
48 Thanks for listening. Resources: SA HIV Clinicians Society Guideline for the prevention, diagnosis and management of cryptococcal meningitis among HIV-infected persons: (2013) DHHS Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents (2018) Special thanks for slides & advice to Yunus Moosa, Raj Gandhi, Graeme Meintjes
49 Cryptococcal antigen (CrAg) screening WHO guidelines recommend CrAg screening in HIV with CD4<100 Ag detectable median 22 days before sxs Pre-emptive antifungal therapy for CrAg (+) HIV-infected patients prevents deaths Meta-analysis suggested that globally pooled prevalence of CrAg (+) is 6.5% in at CD4<100 and 2% in CD CrAg prevalence in inpatients higher (~10%) versus outpatients (~6%) May be reasonable to revise CrAg screening from CD4<100 to CD4<200 & perform routine inpatient CrAg screening Dipstick lateral flow assay for serum or CSF: $2/test and takes 10 min with sensitivity ~99% CID 2018; 66 (S2) S152-9
TB and HIV co-infection including IRIS
TB and HIV co-infection including IRIS Richard Lessells SAHCS Conference 2018 Clinical scenario 1 36-year-old male Presents with cough, fever & weight loss HIV test positive (new diagnosis) Sputum Xpert
More informationCryptococcal Meningitis
Cryptococcal Meningitis Dr N Thumbiran Infectious Diseases Department UKZN Index patient 27 year old female Presented to King Edward Hospital on 17/07/2005 with: Severe headaches Vomiting Photophobia X
More informationChallenges in Management of Cryptococcal Meningitis. Yunus Moosa Department of ID NRMSM Durban
Challenges in Management of Cryptococcal Meningitis Yunus Moosa Department of ID NRMSM Durban Overview Epidemiology Pathogenesis Clinical presentation Diagnosis Prognostic factors Antifungal Treatment
More informationAdvanced HIV and seriously ill: challenges in low resource settings Rosie Burton, Southern African Medical Unit, MSF
Advanced HIV and seriously ill: challenges in low resource settings Rosie Burton, Southern African Medical Unit, MSF Mozambique Mozambique Mozambique Mozambique Preventing mortality MSF hospital, Kinshasa,
More informationA Case of Cryptococcal Meningitis
A Case of Cryptococcal Meningitis DOUGLAS FISH ALBANY MEDICAL COLLEGE JUNE 4, 2013 History Patient transferred from Columbia Memorial Hospital with lethargy, shortness of breath, chest pains and failure
More informationOPPORTUNISTIC INFECTIONS. Institute of Infectious Diseases, Pune India
OPPORTUNISTIC INFECTIONS Institute of Infectious Diseases, Pune India DISCLOSURES Nothing to declare Outline The problem Bacterial Fungal Protozoal Viral Decline in OI prevalence in HAART era: USA CROI
More informationImmune Reconstitution Inflammatory Syndrome. Dr. Lesego Mawela
Immune Reconstitution Inflammatory Syndrome Dr. Lesego Mawela TOPICS FOR DISCUSSION IRIS Case Epidermiology Pathogenesis of IRIS Risk factors for IRIS Epidemiology of IRIS Health system burden of IRIS
More informationCryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease
Cryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease Assist Prof. Somnuek Sungkanuparph Division of Infectious Diseases Faculty of Medicine Ramathibodi Hospital Mahidol
More informationApproach to the critically ill patient with advanced HIV in low resource settings. Sebastian Albus, MD MSF, Operational Center Bruxelles
Approach to the critically ill patient with advanced HIV in low resource settings Sebastian Albus, MD MSF, Operational Center Bruxelles why You should be this guy. instead of that guy ME USFR, Guinea-Conakry
More informationMeningi&s in HIV NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Meningi&s in HIV Christina M. Marra, MD Neurology and Medicine University of Washington School of Medicine Susceptibility to CNS Opportunistic Infections CD4+
More informationOpportunities for improvement
Are there opportunities to manage cryptococcal meningitis better? Signals High-quality evidence Nelesh Govender National Institute for Communicable Diseases Inclusion in guidelines Translation into clinical
More informationAdvanced HIV Disease / AIDS
Advanced HIV Disease / AIDS Technical Summary for Activists Gilles Van Cutsem, SAMU, MSF Objectives Why is increased investment in Advanced HIV Disease (AHD) / AIDS critical? What are the issues? What
More informationChallenge - Advanced HIV in Antiretroviral- Experienced Patients. Esther C. Casas South African Medical Unit Medecins Sans Frontieres
Challenge - Advanced HIV in Antiretroviral- Experienced Patients Esther C. Casas South African Medical Unit Medecins Sans Frontieres The forgotten 4 th 90: HIV related mortality plateauing % of Advance
More informationCD4 WORKSHOP REPORT JULY 22, 2017
CD4 WORKSHOP REPORT JULY 22, 2017 TABLE OF CONTENTS Contents Introduction 1 Strengthening the interface between diagnostics and care treatment monitoring 2 Findings from the first regional CD4 workshop
More informationOutline. A 41 Year-old Male COMMON PITFALLS IN HIV/AIDS MANAGEMENT: A CASE-BASED APPROACH. Q1: What anti-fungal regimen would you start?
Outline COMMON PITFALLS IN HIV/AIDS MANAGEMENT: A CASE-BASED APPROACH Considerations for antiretroviral use in patients with coinfections Concerning and how to manage drug-drug interactions ARV-other drugs
More informationOutline. Cryptococcosis Pneumocystosis Diarrhea. Case Histories: HIV Related- Opportunistic Infections in 2015
AU Edited: 05/06/15 Case Histories: HIV Related- Opportunistic Infections in 2015 Henry Masur, MD Clinical Professor of Medicine George Washington University School of Medicine Bethesda, Maryland Washington,
More informationEfavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST. Graeme Meintjes University of Cape Town
Efavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST Graeme Meintjes University of Cape Town Benefits of dolutegravir Superior efficacy in SINGLE trial Side effect profile
More informationUPDATE IN HOSPITAL MEDICINE
UPDATE IN HOSPITAL MEDICINE FLORIDA CHAPTER ACP MEETING 2016 Himangi Kaushal, M.D., F.A.C.P. Program Director Memorial Healthcare System Internal Medicine Residency DISCLOSURES None OBJECTIVES Review some
More informationManagement of Cryptococcal Meningitis in HIV-infected children in National Pediatric Hospital
Management of Cryptococcal Meningitis in HIV-infected children in National Pediatric Hospital Olivier Marcy 1,2, Sam Sophan 2, Ung Vibol 2, Chan Bunthy 2, Pok Moroun 2, Chy Kam Hoy 2, Ban Thy 2, Chhour
More informationHIV Clinical Management: Antiretroviral Therapy and Drug Resistance
HIV Clinical Management: Antiretroviral Therapy and Drug Resistance Judith S. Currier, MD, MSc Professor of Medicine University of California, Los Angeles Disclosures: Research Grant from Theratechnologies
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More informationWhat is IRIS Types Outline of Presentation Principles behind Case definition of IRIS IRIS cause of early mortality IRIS a factor in optimal timing of
Immune Reconstitution Inflammatory Syndrome: A factor in Timing of Initiation of ART Yunus Moosa UKZN Durban South Africa What is IRIS Types Outline of Presentation Principles behind Case definition of
More informationOpportunistic Infections BHIVA Guidelines
Opportunistic Infections BHIVA Guidelines Mark Nelson David Dockrell Simon Edwards I have.. 1. Read all of the BHIVA guidelines 12% 2. Read some of the BHIVA guidelines in their entirety 3. Browsed some
More informationPneumonia Community-Acquired Healthcare-Associated
Pneumonia Community-Acquired Healthcare-Associated Edwin Yu Clin Infect Dis 2007;44(S2):27-72 Am J Respir Crit Care Med 2005; 171:388-416 IDSA / ATS Guidelines Microbiology Principles and Practice of Infectious
More informationGUIDELINE FOR THE MANAGEMENT OF CRYPTOCOCCAL MENINGITIS
GUIDELINE FOR THE MANAGEMENT OF CRYPTOCOCCAL MENINGITIS Full title of guideline Guideline for the management of cryptococcal meningitis Author Dr P Venkatesan (ID consultant) Division and specialty Medicine,
More informationTreatment of MDR-TB in high HIV- prevalence settings. Hind Satti, M.D. PIH-Lesotho October 20, 2008
Treatment of MDR-TB in high HIV- prevalence settings Hind Satti, M.D. PIH-Lesotho October 20, 2008 Early outcomes of MDR-TB treatment Retrospective cohort analysis Registered between July 21, 2007 and
More informationHIV/TB Co infection TB Clinical Intensive October 11, 2018
HIV/TB Co infection TB Clinical Intensive October 11, 2018 Gabriel Chamie, MD, MPH Associate Professor of Medicine Division of HIV, Infectious Diseases & Global Medicine UCSF/San Francisco General Hospital
More informationOpportunistic infections. Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India
Opportunistic infections Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India Disclosures Advisory board, Speaker fees: Mylan, Hetero, Cipla ltd Outline Why OI s still occur? Mycobacterial
More informationTB & HIV CO-INFECTION IN CHILDREN. Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012
TB & HIV CO-INFECTION IN CHILDREN Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012 Introduction TB & HIV are two of the leading causes of morbidity & mortality in children
More informationKAP conference 19 th March 2008: Dr Mohamed Hussein Jin.
SENSITIVITY PATTERNS, SEROTYPES OF CRYPTOCOCCUS NEOFORMANS AND DIAGNOSTIC VALUE OF INDIA INK IN PATIENTS WITH CRYPTOCOCCAL MENINGITIS AT KENYATTA NATIONAL HOSPITAL. KAP conference 19 th March 2008: Dr
More informationCase Report Diagnosis of Cryptococcosis and Prevention of Cryptococcal Meningitis Using a Novel Point-of-Care Lateral Flow Assay
Case Reports in Medicine Volume 2013, Article ID 640216, 4 pages http://dx.doi.org/10.1155/2013/640216 Case Report Diagnosis of Cryptococcosis and Prevention of Cryptococcal Meningitis Using a Novel Point-of-Care
More informationUrinary TB diagnostics in HIV
Urinary TB diagnostics in HIV SAMRC UCT Eastern Cape collaborative research symposium 20 th October 2017 David Stead Prospective PM study in Zambian tertiary hospital - All medical deaths over 1 year -
More informationAetiology of meningitis at the Moi Teaching and Referral Hospital, Eldoret, Kenya. D. K. Lagat, MBChB, Mmed(Moi)
Aetiology of meningitis at the Moi Teaching and Referral Hospital, Eldoret, Kenya D. K. Lagat, MBChB, Mmed(Moi) Introduction Meningitis is common and important Syndromes of meningitis: Acute bacterial
More informationThe Lancet Infectious Diseases
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study Susan E Dorman, Samuel G Schumacher, David Alland et al. 2017
More informationTB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?
Those oral antibiotics are just not working! Inpatient Standards of Care & Discharge Planning S/He s in the Hospital: Now What Do I Do? Dana G. Kissner, MD TB Intensive Workshop, Lansing, MI 2012 Objectives:
More informationCryptococcal Antigen Screening: Perspectives from Uganda. Dr. David Meya, MMed Dr. David Boulware, MD MPH ASLM, Capetown 2012
Cryptococcal Antigen Screening: Perspectives from Uganda Dr. David Meya, MMed Dr. David Boulware, MD MPH ASLM, Capetown 2012 Introduction Globally, an estimated 957,900 cases of cryptococcal meningitis
More informationTreatment of Cryptococcal Meningitis. Graeme Meintjes University of Cape Town GF Jooste Hospital Imperial College London
Treatment of Cryptococcal Meningitis Graeme Meintjes University of Cape Town GF Jooste Hospital Imperial College London Cryptococcal meningitis Predominantly in HIV infected patients with CD4 < 200 Studies
More informationClinical use of a TB Diagnostic using LAM Detection in Urine. Robin Wood, IDM, University of Cape Town
Clinical use of a TB Diagnostic using LAM Detection in Urine Robin Wood, IDM, University of Cape Town Declaration of Interests Statement Robin Wood, FCP (SA), D.Sc.(Med), FRS (SA). Emeritus Professor of
More informationCommon Fungi. Catherine Diamond MD MPH
Common Fungi Catherine Diamond MD MPH Birth Month and Day & Last Four Digits of Your Cell Phone # BEFORE: http://tinyurl.com/kvfy3ts AFTER: http://tinyurl.com/lc4dzwr Clinically Common Fungi Yeast Mold
More informationThe clinical utility of the urine based lateral flow lipoarabinomannan (LF-LAM) assay in HIV infected adults in Myanmar.
The clinical utility of the urine based lateral flow lipoarabinomannan (LF-LAM) assay in HIV infected adults in Myanmar Josh Hanson Background Tuberculosis is the commonest cause of death in HIV infected
More informationWESTERN CAPE ART GUIDELINES PRESENTATION 2013
WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory
More informationCNS Infections. Philip Gothard Consultant in Infectious Diseases Hospital for Tropical Diseases, London. Hammersmith Acute Medicine 2011
CNS Infections Philip Gothard Consultant in Infectious Diseases Hospital for Tropical Diseases, London Hammersmith Acute Medicine 2011 Case 1 HISTORY 27y man Unwell 3 days Fever Headache Photophobia Previously
More informationWhen to start: guidelines comparison
The editorial staff When to start: guidelines comparison The optimal time to begin antiretroviral therapy remains a critical question for the HIV field, and consensus about the appropriate CD4+ cell count
More informationClinical presentation Opportunistic infections
Clinical presentation Opportunistic infections Assoc Prof. Thanyawee Puthanakit Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University,Bangkok, Thailand
More informationTuberculosis Immune Reconstitution Inflammatory Syndrome (TB- IRIS)
Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB- IRIS) Graeme Meintjes Institute of Infectious Disease and Molecular Medicine (IDM) Wellcome Centre for Infectious Diseases Research in Africa
More informationHIV Management in Resource-Poor Settings
HIV Management in Resource-Poor Settings Research in Progress Eran Bendavid, MD Infectious Diseases Center for Health Policy Outline Context Methods Results Conclusions Discussion Context The number of
More informationCase Presentation. Intern Tutor VS 2007/01/26
Case Presentation Intern 8931150 Tutor VS 2007/01/26 About The Patient 38 years old worker ID: M120794700 Admission date: 2006/12/28 C.C.: Fever with headache for 2 days Present Illness Smoker, alcoholism
More informationSummary I: TB, Opportunistic Infections, HCV/HBV Co-Infections, HPV, STI & Tumors
La Pedrera, Barcelona March 13 th 2018 Summary I: TB, Opportunistic Infections, HCV/HBV Co-Infections, HPV, STI & Tumors Dr. José M. Miró Infectious Diseases Service Hospital Clinic - IDIBAPS University
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals Common Challenges and Mistakes in Managing
More informationOpportunistic infections in the era of cart, still a problem in resource-limited settings
Opportunistic infections in the era of cart, still a problem in resource-limited settings Cristiana Oprea Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania Assessment
More informationFungal Meningitis. Stefan Zimmerli Institute for infectious diseases University of Bern Friedbühlstrasse Bern
Fungal Meningitis Stefan Zimmerli Institute for infectious diseases University of Bern Friedbühlstrasse 51 3010 Bern Death due to infectious diseases in sub-saharan Africa Park BJ. Et al AIDS 2009;23:525
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationUpdate on TB-IRIS. Graeme Meintjes. University of Cape Town Imperial College London
Update on TB-IRIS Graeme Meintjes University of Cape Town Imperial College London SA HIV Clinicians Society Conference, Cape Town, 27 Nov 2012 Paradoxical TB-IRIS Patient diagnosed with TB and started
More informationIsoniazid preventive therapy for HIV+:
Isoniazid preventive therapy for HIV+: Controversial topics Gary Maartens Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Risk of TB disease after
More informationLisa K. Fitzpatrick, MD, MPH Associate Professor of Medicine Howard University School of Medicine
Lisa K. Fitzpatrick, MD, MPH Associate Professor of Medicine Howard University School of Medicine HIV Testing Missed Opportunities Acute Retroviral Syndrome Opportunistic Infections Treatment Reminders
More informationErrors in Dx and Rx of TB
Errors in Dx and Rx of TB David Schlossberg, MD, FACP Professor of Medicine Temple University School of Medicine Medical Director, TB Control Program Philadelphia Department of Public Health TB Still a
More informationModeling the diagnosis of HIVassociated
Modeling the diagnosis of HIVassociated TB: key research questions and data gaps Patrick GT Cudahy, MD Clinical Instructor Yale School of Medicine S L I D E 0 Diagnosis of TB in people living with HIV
More informationINH Prophylaxis Therapy (IPT) should NOT be implemented for all HIV patients in the Asia Pacific
INH Prophylaxis Therapy (IPT) should NOT be implemented for all HIV patients in the Asia Pacific Thuy Le, MD DPhil Duke University School of Medicine, USA Oxford University Clinical Research Unit Hospital
More informationWhen the drugs don t work- a case of HSV encephalitis.
When the drugs don t work- a case of HSV encephalitis. Nicky Price Consultant Virologist Public Health Wales 67 year old Caucasian Female Presenting complaint 2 day history of: Confusion Shivering Headache
More information11/19/2012. The spectrum of pulmonary diseases in HIV-infected persons is broad.
The spectrum of pulmonary diseases in HIV-infected persons is broad. HIV-associated Opportunistic infections Neoplasms Miscellaneous conditions Non HIV-associated Antiretroviral therapy (ART)-associated
More informationAnna Maria Geretti on behalf of co-authors Professor of Virology & Infectious Diseases, University of Liverpool Expert Scientist, Roche Pharma
Anna Maria Geretti on behalf of co-authors Professor of Virology & Infectious Diseases, University of Liverpool Expert Scientist, Roche Pharma Research & Early Discovery Funding: Wellcome Trust, National
More informationAIDS at 25. Epidemiology and Clinical Management MID 37
AIDS at 25 Epidemiology and Clinical Management Blood HIV Transmission transfusion injection drug use Sexual Intercourse heterosexual male to male Perinatal intrapartum breast feeding Regional HIV and
More informationAn Update on TB and OI prophylaxis
An Update on TB and OI prophylaxis Dr Nithendra Manickchund Department of Infectious Diseases Nelson R. Mandela School of Medicine University of KwaZulu-Natal TB Infection Tuberculosis (TB) infection occurs
More informationCerebral Toxoplasmosis in HIV-Infected Patients. Ahmed Saad,MD,FACP
Cerebral Toxoplasmosis in HIV-Infected Patients Ahmed Saad,MD,FACP Introduction Toxoplasmosis: Caused by the intracellular protozoan, Toxoplasma gondii. Immunocompetent persons with primary infection
More informationIsoniazid Prevention Therapy for HIV Positive Patients
Isoniazid Prevention Therapy for HIV Positive Patients Increasing Tuberculosis Prevention for HIV-Patients in Ethiopia QuickTime and a decompressor are needed to see this picture. Ashok Reddy, MD University
More informationCase 1. Background. Presenting Symptoms. Schecter Case1 Differential Diagnosis of TB 1
TB or Not TB? Case 1 Gisela Schecter, M.D., M.P.H. California Department of Public Health Background 26 year old African American male Born and raised in Bay Area of California Convicted of cocaine trafficking
More informationMENINGITIS CRYPTOCOCCAL. learn about the symptoms, diagnosing and treating this disease
CRYPTOCOCCAL MENINGITIS learn about the symptoms, diagnosing and treating this disease A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS JANAURY 2007 Cryptococcal
More informationA Randomized Clinical Trial Comparing 6 EH vs 36H for TB Prevention in HIV-infected Adults in south India: Impact on Mortality
A Randomized Clinical Trial Comparing 6 EH vs 36H for TB Prevention in HIV-infected Adults in south India: Impact on Mortality Soumya Swaminathan,, PA Menon,, P Venkatesan et al Indian Council of Medical
More informationClinical skills building - HIV drug resistance
Clinical skills building - HIV drug resistance Richard Lessells Clinical case 44-year old HIV-positive male HIV diagnosis 2010 Pre-treatment CD4+ count not known Initiated first-line ART (TDF/FTC/EFV)
More informationHIV AND LUNG HEALTH. Stephen Aston Infectious Diseases SpR Royal Liverpool University Hospital
HIV AND LUNG HEALTH Stephen Aston Infectious Diseases SpR Royal Liverpool University Hospital Introduction HIV infection exerts multiple effects on pulmonary immune responses: Generalised state of immune
More informationDr. Andrew D Kambugu The Infectious Diseases Institute, Makerere University College of Health Sciences
The Future of Antiretroviral Therapy in Africa: Perspectives from Uganda Dr. Andrew D Kambugu The Infectious Diseases Institute, Makerere University College of Health Sciences Discussion Outline A. Characteristics
More informationTB prevention studies in PLHIV: recent updates and what can they tell us for the future?
TB prevention studies in PLHIV: recent updates and what can they tell us for the future? Richard E. Chaisson, MD Center for AIDS Research Center for TB Research Johns Hopkins University TB/HIV Working
More informationComparative performance of emerging rapid diagnostics in HIV-infected individuals
Comparative performance of emerging rapid diagnostics in HIV-infected individuals Maunank Shah M.D. Johns Hopkins University Clinical Diagnostics Research Consortium Background Emerging diagnostics may
More informationHIV Viral Load Testing Market Analysis. September 2012 Laboratory Services Team Clinton Health Access Initiative
HIV Viral Load Testing Market Analysis September 2012 Laboratory Services Team Clinton Health Access Initiative Agenda Background on Viral Load Testing Growth of Global Viral Load Market Factors Impacting
More informationAIDS at 30 Epidemiology and Clinical Epidemiology and Management MID 37
AIDS at 30 Epidemiology and Clinical Management Blood HIV Transmission transfusion injection drug use Sexual Intercourse heterosexual male to male Perinatal intrapartum breast feeding Adults and children
More informationRandomized Placebo-controlled Trial of Prednisone for the TB-Immune Reconstitution Inflammatory Syndrome
Randomized Placebo-controlled Trial of Prednisone for the TB-Immune Reconstitution Inflammatory Syndrome Graeme Meintjes 1,2, Robert J Wilkinson 1,2,3,4, Chelsea Morroni 1, Dominique Pepper 1,2, Kevin
More informationAWACC-2011 ART in the Inpatient Setting
AWACC-2011 ART in the Inpatient Setting Why no ART preparation for inpatients? 1.No link between inpatient and outpatient programmes HIV and AIDS services are delivered by well-funded but separate vertical
More informationPRIORITIES FOR HIV/AIDS PROCUREMENT AND PRODUCT DEVELOPMENT
PRIORITIES FOR HIV/AIDS PROCUREMENT AND PRODUCT DEVELOPMENT Dr Chewe Luo MMed (Paeds), Mtrop Paed, PhD Senior Adviser and Team Leader Country Programme Scale up HIV Section Programme Division UNICEF, NY
More informationDidactic Series. Fungal Infections: small bother to big mortality
Didactic Series Fungal Infections: small bother to big mortality Christian B. Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic 8/8/13 ACCREDITATION STATEMENT: University of California,
More informationand the Working Group from the EMBO-AIDS Related Mycoses Workshop Institute of Infectious Disease and Molecular Medicine, University of Cape Town,
1 AIDS-related mycoses: the way forward Gordon D. Brown 1,2*, Graeme Meintjes 1, Jay K. Kolls 3, Clive Gray 1, William Horsnell 1 and the Working Group from the EMBO-AIDS Related Mycoses Workshop 1 Institute
More informationWho Is Dying and Why? AIDS Mortality as a Progress Metric
Who Is Dying and Why? AIDS Mortality as a Progress Metric Sharonann Lynch HIV & TB Policy Advisor MSF Access Campaign 1 OUTLINE 1. Trends in mortality 2. Finding the RIPs among the LTFU 3. Who is dying
More informationReasons why we will never forget. Andrea Antinori INMI L. Spallanzani IRCCS, Roma
Reasons why we will never forget Andrea Antinori INMI L. Spallanzani IRCCS, Roma SMRs according to time spent with CD4 count >500/mm3 after cart initiation in MSM 80,642 HIV-infected individuals eligible
More informationCommunity Acquired & Nosocomial Pneumonias
Community Acquired & Nosocomial Pneumonias IDSA/ATS 2007 & 2016 Guidelines José Luis González, MD Clinical Assistant Professor of Medicine Outline Intro - Definitions & Diagnosing CAP treatment VAP & HAP
More informationHIV DRUG RESISTANCE IN AFRICA
HIV DRUG RESISTANCE IN AFRICA Francis Ssali Joint Clinical Research Centre, Kampala Interest Meeting Mombasa May 10 th 2012 Scope 1. HIV-DR testing in Africa 2. The Epidemiology of HIV-DR in Africa 3.
More informationOriginal Article. Noparat Oniem, M.D., Somnuek Sungkanuparph, M.D.
Original Article Vol. 29 No. 1 Primary prophylaxis for cryptococcosis with fluconazole:- Oniem N & Sungkanuparph S. 5 Primary prophylaxis for cryptococcosis with fluconazole among HIV-infected patients
More informationTreatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand
Treatment experience in South Africa Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand Overview South African Prevalence Adherence Combination ddi + d4t Nevirapine Hepatotoxicity
More informationCare of HIV Infected People
Care of HIV Infected People Patrick Ndase, MD, MPH MTN Annual Meeting Marriott Key Bridge, Arlington, VA April 21-23, 2008 Why Care for HIV infected in such a meeting? Site Core Community Why Care for
More informationTuberculosis in children: gaps and opportunities
Tuberculosis in children: gaps and opportunities Mark Nicol Division of Medical Microbiology and Institute for Infectious Diseases and Molecular Medicine, University of Cape Town and National Health Laboratory
More informationManagement of Immune Reconstitution Inflammatory Syndrome (IRIS)
Management of Immune Reconstitution Inflammatory Syndrome (IRIS) Adult Clinical Guideline from the New York State Department of Health AIDS Institute www.hivguidelines.org Purpose of the IRIS Guideline
More informationECMM Excellence Centers Quality Audit
ECMM Excellence Centers Quality Audit Person in charge: Department: Head of Department: Laboratory is accredited according to ISO 15189 (Medical Laboratories Requirements for quality and competence) Inspected
More informationTB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009
TB Intensive Houston, Texas November 10-12, 12 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 1 OUTLINE Stages
More informationCULTURE OR PCR WHAT IS
CULTURE OR PCR WHAT IS BEST FOR AFRICA? Peter R Mason BRTI TB IN AFRICA GLOBAL 9 MILLION NEW CASES/YR 1.5 MILLION TB DEATHS AFRICA 95% TB DEATHS IN LMIC 9/22 HIGH BURDEN COUNTRIES IN AFRICA STRONG LINK
More informationTuberculosis and HIV: key issues in diagnosis and management
Tuberculosis and HIV: key issues in diagnosis and management Julian Elliott Infectious Diseases Unit, Alfred Hospital Centre for Population Health, Burnet Institute julian.elliott@alfred.org.au Outline
More informationEvolving Realities of HIV Treatment in Resource-limited Settings
Evolving Realities of HIV Treatment in Resource-limited Settings Papa Salif Sow MD, MSc Department of Infectious Diseases University of Dakar, Senegal Introduction: ARV access in RLS Scale-up of ART has
More informationOI prophylaxis When to start, when to stop. Eva Raphael, MD MPH Family and community medicine, pgy-2 University of California, San Francisco
OI prophylaxis When to start, when to stop Eva Raphael, MD MPH Family and community medicine, pgy-2 University of California, San Francisco Learning Objectives o Recognize when to start OI prophylaxis
More informationGeneral History. 林陳 珠 Female 69 years old 住院期間 : ~ Chief Complaint : sudden loss of conscious 5 minutes in the morning.
General History 林陳 珠 Female 69 years old 住院期間 : 93.5.8~93.5.15 Chief Complaint : sudden loss of conscious for 2-52 5 minutes in the morning. General History DM under regular medical control for 10 years.
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationGenotypic Resistance Testing in Routine Care in South Africa:
Genotypic Resistance Testing in Routine Care in South Africa: Is the Juice Worth the Squeeze? Mark Siedner Africa Health Research Institute Harvard Medical School Conflicts of Interest^* No financial conflicts
More informationMDS Mentorship Experience
MDS Mentorship Experience MENTOR: CARRIE KOVARIK, MD UNIVERSITY OF PENNSYLVANIA MENTEE: MONICA RANI, MD UNIVERSITY OF MINNESOTA NORTHWESTERN UNIVERSITY From Philadelphia ------ > Kampala, Uganda COAT
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More information